Lantheus (NASDAQ:LNTH) Hits New 1-Year High – What’s Next?

Lantheus Holdings, Inc. (NASDAQ:LNTH) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $107.99 and last traded at $106.8160, with a volume of 147583 shares changing hands. The stock had previously closed at $106.20.

Wall Street Analyst Weigh In

Several research firms have recently commented on LNTH. JonesTrading lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Mizuho lifted their target price on Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. William Blair reissued an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Finally, Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Stock Performance

The firm has a fifty day moving average price of $93.86 and a 200 day moving average price of $78.71. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. The stock has a market cap of $6.96 billion, a PE ratio of 25.75 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. During the same period in the previous year, the business earned $1.53 EPS. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts forecast that Lantheus Holdings, Inc. will post 4.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lantheus

Hedge funds have recently modified their holdings of the stock. Western Wealth Management LLC acquired a new stake in Lantheus in the 1st quarter worth approximately $25,000. Osterweis Capital Management Inc. purchased a new position in shares of Lantheus in the second quarter worth $36,000. Smartleaf Asset Management LLC raised its holdings in shares of Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 197 shares during the last quarter. Bessemer Group Inc. lifted its stake in shares of Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 354 shares during the period. Finally, Parallel Advisors LLC lifted its stake in shares of Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 298 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.